# suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

> **NCT07466524** · — · COMPLETED · sponsor: **ViroGates A/S** · enrollment: 367 (actual)

## Conditions studied

- COVID-19
- Severe Respiratory Distress Syndrome
- Acute Respiratory Distress Syndrome

## Interventions

- **DIAGNOSTIC_TEST:** suPARnostic® TurbiLatex Assay on Roche cobas c501

## Key facts

- **NCT ID:** NCT07466524
- **Lead sponsor:** ViroGates A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-10-19
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466524, "suPAR Michigan M2C2 Heterogeneity Validation Cohort Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07466524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*